Biora Therapeutics undertakes Chapter 11 sale process to position business for future growth.
Learn more
Biora Therapeutics Home
Activate the mobile navigation
Close the mobile navigation
Close
Home
Company
About
Leadership
Quality
Careers
Platforms
BioJet Oral Therapeutic Delivery
NaviCap Targeted Therapeutic Delivery
Publications
Investors
Press Releases
Events & Presentations
SEC Filings
Governance Documents
Investor FAQs
Investor Email Alerts
Contact
Toggle the search bar
Search the Site
Close the mobile navigation
Publications
Select Category
Select Category...
BioJet Oral Therapeutic Delivery
NaviCap Targeted Therapeutic Delivery
SIBO & Microbiome
Development of a novel drug delivery system to deliver drugs directly to the colonic mucosa
July 7, 2021
#NaviCap Targeted Therapeutic Delivery
Development of a novel drug delivery system for targeted treatment of ulcerative colitis
May 20, 2021
#NaviCap Targeted Therapeutic Delivery
Targeted delivery of tofacitinib citrate to the site of disease to improve efficacy and safety
May 20, 2021
#NaviCap Targeted Therapeutic Delivery
Targeted topical anti-α4β7 integrin antibody results in reduced accumulation of α4β7 memory T-cells in gut tissue in DSS-induced colitis mice
October 28, 2019
#NaviCap Targeted Therapeutic Delivery
1
2
Connect with us
Email Us
Biora Therapeutics Linkedin
Biora Therapeutics Twitter